ArticleBMJ medicine2022
Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness.
Article in BMJ medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.BMC medical research methodology · 2025Trial
- General-Purpose Methods for Simulating Survival Data for Expected Value of Sample Information Calculations.Medical decision making : an international journal of the Society for Medical Decision Making · 2023Trial
- Flexible Survival Extrapolation with Blended Hazards: Accounting for Treatment Effect Waning in Health Technology Assessment.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- A Scoping Review of Methods for Extrapolating Costs and Effects in Economic Evaluations of Remote Monitoring.PharmacoEconomics - open · 2026Review
- Economic Evaluation of Interventions for Children with Neurodevelopmental Disorders: Practical Guidance.PharmacoEconomics · 2026Review
- Prediction Error in Quality-Adjusted Life Years in Economic Evaluations of Immune Checkpoint Inhibitors: A Comparison Based on Projected and Observed Updated Survival.PharmacoEconomics - open · 2026Article
- Cost-Effectiveness of First-Line Immunochemotherapy VersusCurrent oncology (Toronto, Ont.) · 2026Article
- Developing shortcut algorithms for value-based pricing of pharmaceuticals.Health economics review · 2026Article
- The evolution of cancer therapies and their Implications for health technology assessment in Australia.Cost effectiveness and resource allocation : C/E · 2026Review
- Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.Cost effectiveness and resource allocation : C/E · 2026Article
- Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial.Frontiers in public health · 2026Article
- CAR-T cell therapies: patient access and affordability solutions.Future science OA · 2025Review
- Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma.Transplantation and cellular therapy · 2025Article
- Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements.Cost effectiveness and resource allocation : C/E · 2025Article
- Relative Survival Modeling for Appraising the Cost-Effectiveness of Life-Extending Treatments: An Application to Tafamidis for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy.Medical decision making : an international journal of the Society for Medical Decision Making · 2025Article
- Advances and critical aspects in cancer treatment development using digital twins.Briefings in bioinformatics · 2025Review
- Adaptive Weight Selection for Time-To-Event Data Under Non-Proportional Hazards.Statistics in medicine · 2025Article
- Cost-Effectiveness of Clinical Decision Support to Improve CKD Outcomes Among First Nations Australians.Kidney international reports · 2025Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.